A Phase I Study of DCC-2701 in Patients with Advanced Solid Tumors

Full Title

A Multicenter Phase I Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors

Purpose

The purpose of this study is to find the highest dose of the investigational drug DCC-2701 that can be given safely in patients with advanced solid tumors containing MET or TRK genetic mutations. These mutations may fuel cancer growth. DCC-2701 is designed to block growth signals in tumors with MET or TRK mutations.

DCC-2701 is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that cannot be successfully treated with standard therapies and which contains a MET or TRK mutation.
  • Patients must recover from the serious side effects of prior therapies before entering the study.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Alexander Drilon at 646-888-4206.

Protocol

16-1130

Phase

I

Investigator

Co-Investigators

Locations